zonisamide has been researched along with Disease Exacerbation in 4 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study examined whether zonisamide (ZNS) cotreatment delays dopamine transporter (DAT) reduction on SPECT in Parkinson disease (PD) patients." | 7.88 | Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. ( Hirayama, T; Ikeda, K; Ishikawa, Y; Iwasaki, Y; Kano, O; Kawabe, K; Miura, K; Mizumura, N; Takazawa, T; Yanagihashi, M, 2018) |
| "Cervical spondylotic myelopathy (CSM) is caused by chronic compression of the spinal cord and is the most common cause of myelopathy in adults." | 5.56 | Zonisamide ameliorates progression of cervical spondylotic myelopathy in a rat model. ( Imagama, S; Inoue, T; Ishiguro, N; Ito, M; Kanbara, S; Koshimizu, H; Masuda, A; Nakashima, H; Ohkawara, B; Ohno, K; Ohta, K; Tomita, H, 2020) |
| "Zonisamide is an antiepileptic drug mainly used in patients with refractory epilepsy." | 5.39 | [Bilateral urolithiasis with zonisamide developed for a short period of time in a 10-year-old girl with intractable epilepsy]. ( Hirobe, M; Nishinaka, K; Sato, S; Takahashi, S; Tsukamoto, T, 2013) |
| "This study examined whether zonisamide (ZNS) cotreatment delays dopamine transporter (DAT) reduction on SPECT in Parkinson disease (PD) patients." | 3.88 | Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study. ( Hirayama, T; Ikeda, K; Ishikawa, Y; Iwasaki, Y; Kano, O; Kawabe, K; Miura, K; Mizumura, N; Takazawa, T; Yanagihashi, M, 2018) |
| "Cervical spondylotic myelopathy (CSM) is caused by chronic compression of the spinal cord and is the most common cause of myelopathy in adults." | 1.56 | Zonisamide ameliorates progression of cervical spondylotic myelopathy in a rat model. ( Imagama, S; Inoue, T; Ishiguro, N; Ito, M; Kanbara, S; Koshimizu, H; Masuda, A; Nakashima, H; Ohkawara, B; Ohno, K; Ohta, K; Tomita, H, 2020) |
| "The lacosamide treatment pathway was associated with higher costs (i." | 1.51 | Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system. ( Charokopou, M; Christou, P; Geitona, M; Giannakodimos, S; Kimiskidis, VK; Kountouris, V; Stamuli, E, 2019) |
| "Zonisamide is an antiepileptic drug mainly used in patients with refractory epilepsy." | 1.39 | [Bilateral urolithiasis with zonisamide developed for a short period of time in a 10-year-old girl with intractable epilepsy]. ( Hirobe, M; Nishinaka, K; Sato, S; Takahashi, S; Tsukamoto, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanbara, S | 1 |
| Ohkawara, B | 1 |
| Nakashima, H | 1 |
| Ohta, K | 1 |
| Koshimizu, H | 1 |
| Inoue, T | 1 |
| Tomita, H | 1 |
| Ito, M | 1 |
| Masuda, A | 1 |
| Ishiguro, N | 1 |
| Imagama, S | 1 |
| Ohno, K | 1 |
| Ikeda, K | 1 |
| Yanagihashi, M | 1 |
| Miura, K | 1 |
| Ishikawa, Y | 1 |
| Hirayama, T | 1 |
| Takazawa, T | 1 |
| Kano, O | 1 |
| Kawabe, K | 1 |
| Mizumura, N | 1 |
| Iwasaki, Y | 1 |
| Geitona, M | 1 |
| Stamuli, E | 1 |
| Giannakodimos, S | 1 |
| Kimiskidis, VK | 1 |
| Kountouris, V | 1 |
| Charokopou, M | 1 |
| Christou, P | 1 |
| Sato, S | 1 |
| Nishinaka, K | 1 |
| Takahashi, S | 1 |
| Hirobe, M | 1 |
| Tsukamoto, T | 1 |
4 other studies available for zonisamide and Disease Exacerbation
| Article | Year |
|---|---|
Zonisamide ameliorates progression of cervical spondylotic myelopathy in a rat model.
Topics: Animals; Cervical Vertebrae; Disease Models, Animal; Disease Progression; Female; Motor Neurons; Rat | 2020 |
Zonisamide cotreatment delays striatal dopamine transporter reduction in Parkinson disease: A retrospective, observational cohort study.
Topics: Aged; Antiparkinson Agents; Corpus Striatum; Disease Progression; Dopamine Plasma Membrane Transport | 2018 |
Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system.
Topics: Adult; Anticonvulsants; Computer Simulation; Cost-Benefit Analysis; Disease Progression; Epilepsies, | 2019 |
[Bilateral urolithiasis with zonisamide developed for a short period of time in a 10-year-old girl with intractable epilepsy].
Topics: Anticonvulsants; Child; Dehydration; Disease Progression; Epilepsy, Tonic-Clonic; Female; Humans; Hy | 2013 |